Core Viewpoint - Rowley Law PLLC is investigating potential securities law violations related to the proposed acquisition of iTeos Therapeutics, Inc. by Concentra Biosciences, LLC, with stockholders set to receive $10.047 and one contingent value right for each share held [1]. Group 1 - The proposed acquisition transaction is expected to close in the third quarter of 2025 [1]. - Stockholders of iTeos Therapeutics will receive a total of $10.047 per share along with one contingent value right [1].

NEW YORK, July 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=157181&from=4CLASS PERIOD: April 29, ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to alleged misleading statements and concealment of material facts related to the company's capital allocation and dividend strategy [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Organon & Co. provided overly positive statements to investors while concealing significant adverse facts about its priorities, particularly regarding capital allocation and a debt reduction strategy following the acquisition of Dermavant [3]. - The company reportedly reduced its regular quarterly dividend by 70%, which was not disclosed to investors prior to the announcement [3]. Stock Price Impact - Following the announcement of the dividend cut, Organon's stock price fell from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [3]. Class Action Details - The class period for the lawsuit is defined as October 31, 2024, to April 30, 2025, and shareholders are encouraged to register for participation in the class action [3][4]. - The deadline for shareholders to seek lead plaintiff status is July 22, 2025, and there is no cost or obligation to participate in the case [4]. Firm's Commitment - The Gross Law Firm emphasizes its mission to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements [5].

Core Viewpoint - A lawsuit is pending against Pacira BioSciences, Inc. for alleged violations of securities laws related to misleading statements about patent protections for its product Exparel, which is critical for the company's revenue growth [2]. Group 1: Lawsuit Details - An investor filed a lawsuit on January 13, 2025, claiming that Pacira made false statements regarding the patent protections for Exparel, which accounts for approximately 80% of the company's revenue [2]. - The lawsuit alleges that Pacira misrepresented the strength of the '495 patent, which was invalidated in a separate case, leading to concerns that generic competition could arise during the patent's life [2]. Group 2: Investor Information - Shareholders who purchased Pacira BioSciences, Inc. shares prior to August 2023 and continue to hold them are encouraged to contact the Shareholders Foundation for options related to the lawsuit [1][3].

Group 1 - The Schall Law Firm is investigating claims on behalf of investors of BellRing Brands, Inc. for potential violations of securities laws [1] - The investigation centers on whether BellRing made false or misleading statements and failed to disclose important information to investors [2] - During its Q2 earnings call on May 6, 2026, BellRing announced that Q3 sales growth would slow to "low-single-digits" due to customers optimizing inventories, leading to a nearly 19% drop in shares on the same day [2]

Group 1 - The Schall Law Firm is investigating claims on behalf of investors of Laser Photonics Corporation for potential violations of securities laws [1] - The investigation centers on whether Laser Photonics issued false or misleading statements and failed to disclose important information to investors [2] - Laser Photonics received a notice from Nasdaq regarding its non-compliance with listing rules due to delinquent filings, leading to a more than 6.5% drop in its share price [2]

LOS ANGELES, July 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of KBR, Inc. ("KBR" or "the Company") (NYSE: KBR) for violations of the securities laws. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335 [email protected] www.schallfirm.com The investigation focus ...

Core Viewpoint - The Schall Law Firm is investigating Centene Corporation for potential violations of securities laws, particularly regarding misleading statements and undisclosed information that may have affected investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Centene issued false or misleading statements and failed to disclose critical information to investors [2]. - A Seeking Alpha report indicated that Centene's shares declined after the company withdrew its 2025 earnings guidance, citing higher-than-expected costs related to Medicaid enrollees and underperformance in its Affordable Care Act plans [2]. - Following the announcement, Centene's shares fell by more than 39.5% during intraday trading on the same day [2]. Group 2: Company Background - Centene Corporation is involved in providing healthcare services, particularly through Medicaid and Affordable Care Act plans [2]. - The company reported a significant increase in medical cost trends in areas such as behavioral health, home health, and high-cost drugs [2].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its lead product candidate, PGN-EDO51, and its clinical study, CONNECT2 [1][2]. Allegations - The lawsuit claims that during the class period from March 7, 2024, to March 3, 2025, PepGen misrepresented the effectiveness and safety of PGN-EDO51 [1]. - It is alleged that the CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study [1]. - The complaint states that the clinical, regulatory, and commercial prospects of PGN-EDO51 were overstated, making the company's public statements materially false and misleading [1]. Class Action Details - Shareholders who purchased shares of PepGen during the specified class period are encouraged to register for the class action by August 8, 2025 [2]. - Registration allows shareholders to receive updates on the case and does not incur any costs or obligations [2]. Law Firm Background - The Gross Law Firm is recognized for its commitment to protecting investors' rights against deceit and fraud, aiming to hold companies accountable for misleading practices [3].

Core Viewpoint - Berger Montague is investigating potential securities law violations involving Petco Health and Wellness Company, Inc., following a class action lawsuit filed on behalf of investors who acquired Petco securities between January 14, 2021, and June 5, 2025 [1][2] Company Overview - Petco, headquartered in San Diego, CA, focuses on enhancing the lives of pets and pet parents [2] Allegations and Financial Impact - The complaint alleges that Petco made materially false and misleading statements regarding its pandemic-related tailwinds and the sustainability of its premium pet food business model [3] - It is claimed that the company overstated its ability to deliver profitable growth while downplaying operational challenges, leading to significant declines in Petco's stock price [3] - Notably, Petco's stock price dropped by more than 20% on August 24, 2023, following a downward revision of financial guidance, with further declines after subsequent disclosures and leadership changes [3]